In recent years, a variety of TKIs targeting at BCR-ABL with increasing specificity and efficacy have been developed, which have fundamentally promoted the treatment of CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.